Galenica demonstrates pleasing growth and improves EBIT guidance
|
Galenica AG / Key word(s): Half Year Results
Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%2) and the consumer healthcare market (+0.6%3). Strong sales growth in prescription drugsFollowing an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based4 weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year. Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT1 increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT1 would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment. Improved EBIT guidance for the second half of the yearGalenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT1 increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected. In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance. Key figures of the Galenica Group in the first half of 2025
1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the half year report 2025) 2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025. 3) IQVIA, Consumer Health Market Switzerland, YTD June 2025. 4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.
Detailed information in the half year report 2025:
Upcoming dates
For further information, please contact:
Welcome to the Galenica network! Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com. End of Inside Information |
| Language: | English |
| Company: | Galenica AG |
| Untermattweg 8 | |
| 3027 Bern | |
| Switzerland | |
| Phone: | +41 058 852 81 11 |
| E-mail: | info@galenica.com |
| Internet: | https://www.galenica.com |
| ISIN: | CH0360674466 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2180242 |
| End of Announcement | EQS News Service |
|
|
2180242 07-Aug-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.